---
title: "Brimonidine - Ocular Hypertension - 2"
sidebar: mydoc_sidebar
permalink: db00484-mesh-d009798-2.html
toc: false 
---


Path ID: `DB00484_MESH_D009798_2`
{% include image.html url="images/db00484-mesh-d009798-2.png" file="db00484-mesh-d009798-2.png" alt="db00484-mesh-d009798-2" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| <a href="https://identifiers.org/MESH:D000068438">MESH:D000068438 </a> | brimonidine | Drug |
| <a href="https://identifiers.org/UniProt:P08913">UniProt:P08913 </a> | Alpha-2A adrenergic receptor | Protein |
| <a href="https://identifiers.org/UniProt:P18089">UniProt:P18089 </a> | Alpha-2B adrenergic receptor | Protein |
| <a href="https://identifiers.org/UniProt:P18825">UniProt:P18825 </a> | Alpha-2C adrenergic receptor | Protein |
| <a href="https://identifiers.org/reactome:R-HSA-418594">reactome:R-HSA-418594 </a> | G alpha (i) signalling events | Pathway |
| <a href="https://identifiers.org/reactome:R-HSA-418597">reactome:R-HSA-418597 </a> | G alpha (z) signalling events | Pathway |
| <a href="https://identifiers.org/CHEBI:17489">CHEBI:17489 </a> | 3,5-cyclic AMP | ChemicalSubstance |
| <a href="https://identifiers.org/GO:0006939">GO:0006939 </a> | smooth muscle contraction | BiologicalProcess |
| <a href="https://identifiers.org/UBERON:0001796">UBERON:0001796 </a> | aqueous humor of eyeball | GrossAnatomicalStructure |
| <a href="https://identifiers.org/UBERON:0003956">UBERON:0003956 </a> | aqueous drainage system | GrossAnatomicalStructure |
| <a href="https://identifiers.org/MESH:D009798">MESH:D009798 </a> | Ocular hypertension | Disease |
|------------|------|---------|

## Relationships


NOTE: predicates are annotated in <a href="https://github.com/biolink/biolink-model/releases/tag/v1.3.0">Biolink Model (v1.3.0)</a>

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Brimonidine | INCREASES ACTIVITY OF | Alpha-2A Adrenergic Receptor |
| Brimonidine | INCREASES ACTIVITY OF | Alpha-2B Adrenergic Receptor |
| Brimonidine | INCREASES ACTIVITY OF | Alpha-2C Adrenergic Receptor |
| Alpha-2A Adrenergic Receptor | PARTICIPATES IN | G Alpha (I) Signalling Events |
| Alpha-2B Adrenergic Receptor | PARTICIPATES IN | G Alpha (I) Signalling Events |
| Alpha-2C Adrenergic Receptor | PARTICIPATES IN | G Alpha (I) Signalling Events |
| Alpha-2A Adrenergic Receptor | PARTICIPATES IN | G Alpha (Z) Signalling Events |
| Alpha-2B Adrenergic Receptor | PARTICIPATES IN | G Alpha (Z) Signalling Events |
| Alpha-2C Adrenergic Receptor | PARTICIPATES IN | G Alpha (Z) Signalling Events |
| G Alpha (I) Signalling Events | DECREASES ABUNDANCE OF | 3,5-Cyclic Amp |
| G Alpha (Z) Signalling Events | DECREASES ABUNDANCE OF | 3,5-Cyclic Amp |
| 3,5-Cyclic Amp | POSITIVELY CORRELATED WITH | Aqueous Humor Of Eyeball |
| 3,5-Cyclic Amp | REGULATES | Smooth Muscle Contraction |
| Smooth Muscle Contraction | REGULATES | Aqueous Drainage System |
| Aqueous Humor Of Eyeball | POSITIVELY CORRELATED WITH | Ocular Hypertension |
| Aqueous Drainage System | NEGATIVELY CORRELATED WITH | Ocular Hypertension |
|---------|-----------|---------|

Comment: UBERON:0003956 includes the uveoscleral network as well as other canals for aqueous humor drainage. The uveoscleral network is the structure that seems to be affected by alpha adrenergic agonists, such as brimonidine, specially in long-term treatments (i.e. chronic dosing).

Reference: 
  - [https://go.drugbank.com/drugs/DB00484#mechanism-of-action](https://go.drugbank.com/drugs/DB00484#mechanism-of-action)
  - [https://en.wikipedia.org/wiki/Brimonidine#Mechanism_of_action](https://en.wikipedia.org/wiki/Brimonidine#Mechanism_of_action)
  - [https://en.wikipedia.org/wiki/Aqueous_humour#Clinical_significance](https://en.wikipedia.org/wiki/Aqueous_humour#Clinical_significance)
  - [https://en.wikipedia.org/wiki/Ciliary_body#Clinical_significance](https://en.wikipedia.org/wiki/Ciliary_body#Clinical_significance)
